LLY

1,117.69

-1.68%↓

JNJ

236.69

-1.62%↓

ABBV

222.09

-2.4%↓

UNH

404.42

-0.94%↓

MRK

115.5

-3.1%↓

LLY

1,117.69

-1.68%↓

JNJ

236.69

-1.62%↓

ABBV

222.09

-2.4%↓

UNH

404.42

-0.94%↓

MRK

115.5

-3.1%↓

LLY

1,117.69

-1.68%↓

JNJ

236.69

-1.62%↓

ABBV

222.09

-2.4%↓

UNH

404.42

-0.94%↓

MRK

115.5

-3.1%↓

LLY

1,117.69

-1.68%↓

JNJ

236.69

-1.62%↓

ABBV

222.09

-2.4%↓

UNH

404.42

-0.94%↓

MRK

115.5

-3.1%↓

LLY

1,117.69

-1.68%↓

JNJ

236.69

-1.62%↓

ABBV

222.09

-2.4%↓

UNH

404.42

-0.94%↓

MRK

115.5

-3.1%↓

Search

Alnylam Pharmaceuticals Inc

Open

SectorHealthcare

284.93 0.9

Overview

Share price change

24h

Current

Min

279.31

Max

285.43

Key metrics

By Trading Economics

Income

20M

206M

Sales

70M

1.2B

P/E

Sector Avg

73.592

49.052

EPS

1.99

Profit margin

17.649

Employees

2,500

EBITDA

7.1M

152M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+61.24% upside

Dividends

By Acuity

Next Earnings

30 lip 2026

Market Stats

By TradingEconomics

Market Cap

-2.2B

39B

Previous open

284.03

Previous close

284.93

News Sentiment

By Acuity

50%

50%

146 / 342 Ranking in Healthcare

Alnylam Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

About Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
help-icon Live chat